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Introduction
In type 2 diabetes mellitus (DM2) plasma levels of non-
esterified fatty acids (NEFA) are increased. Changes in
plasma levels of NEFA are associated with changes in
myocardial triglyceride (TG) content and with changes in
myocardial function in healthy subjects. Whether this
flexibility of myocardial TG can also be induced in DM2
is yet unknown.
Purpose
To determine in uncomplicated DM2 whether different
levels of plasma NEFA induce changes in myocardial TG
content and myocardial function.
Materials and methods
Myocardial TG content and left ventricular (LV) function
were determined using proton magnetic resonance spec-
troscopy and MRI respectively at 1.5 T (Gyroscan ACS/
NT15, Philips) in 9 subjects with uncomplicated DM2
(mean age ± SE: 58.9 ± 1.6 yrs, BMI 26.4 ± 1.0 kg/m2,
HbA1c: 6.0 ± 0.2%) before and after 3 days of a very low
calorie diet (VLCD, 473 kcal/day, to increase plasma lev-
els of NEFA) and after 3 days of a VLCD complemented
with the administration of acipimox (4 × 250 mg during
the last day of caloric restriction, to decrease plasma levels
of NEFA). The percentage (%) of myocardial TG was cal-
culated as TG/water × 100. Myocardial function was calcu-
lated as ejection fraction (EF) for systolic function, and the
ratio between early and atrial filling phase (E/A ratio) for
diastolic function.
Results
Plasma NEFA significantly increased after the VLCD (from
0.51 ± 0.08 to 0.91 ± 0.15 mmol/l, P < 0.05), whereas
plasma NEFA were significantly decreased after acipimox
administration (0.24 ± 0.05 mmol/l, P < 0.05, Figure 1A).
Myocardial %TG at baseline was 0.66 ± 0.11% and
increased to 0.93 ± 0.18% after the VLCD (P < 0.05)
which was reversed after the acipimox (0.81 ± 0.19%, P =
0.17 vs. baseline, Figure 1B). LV EF did not change after
both interventions compared to baseline. However,
diastolic E/A ratio was significantly decreased after the
VLCD (from 1.02 ± 0.17 at baseline to 0.91 ± 0.21 after
the VLCD, P < 0.01) but remained unchanged after acipi-
mox (0.96 ± 0.24, Figure 1C).
Conclusion
A short-term VLCD induces myocardial TG accumulation
in patients with uncomplicated DM2, and is associated
with changes in diastolic function. Administration of
acipimox during the VLCD reduced myocardial TG accu-
mulation together with plasma levels of NEFA and
showed no effects on diastolic heart function. These data
stress the relevance of elevated levels of NEFA in DM2.
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Changes in plasma NEFA (A) and changes in myocardial TG content (B)Figur  1
Changes in plasma NEFA (A) and changes in myocardial TG 
content (B). Diastolic E/A ratio is decreased after the VLCD, 
but unchanged after acipimox administration (C). NEFA = 
non-esterified fatty acids, TG = triglyceride, VLCD = very 
low calorie diet, E = early, A = atrial. * P < 0.05.
